Key result
Managing anticoagulation in neonates on ECMO is highly challenging due to their developing hemostatic system, placing them at significant risk for both life-threatening hemorrhage and thrombosis.
Neonatal ECMO requires complex anticoagulation management due to the immature hemostatic system, necessitating careful monitoring to prevent severe bleeding and thrombotic complications.
Underscores high hemorrhage and thrombosis risks in neonatal ECMO; leaves optimal anticoagulation strategies open for prospective trials.
Extracorporeal membrane oxygenation (ECMO) is becoming increasingly utilized to manage neonates with cardiac and respiratory failure. The procedure involves extensive anticoagulation in a sick neonate with underlying disease pathology. In addition, the immature hemostatic system in the neonate adds to the complexity of titrating the necessary anticoagulation. This places the infant at greater risk for life threatening hemorrhage and thrombosis. Managing anticoagulation in these infants is extremely challenging and needs the expertise of a physician with a thorough knowledge of the intricacies of developmental hemostasis and limitations of the current laboratory techniques available to manage anticoagulation. This article provides a brief overview of the developing hemostatic system of the neonate and the challenges associated with managing anticoagulation in this vulnerable population of patients.
No takes yet. Share an insight, caveat, or question.
Ommen et al. (2018) conducted a review in Neonatal respiratory and cardiac failure. Extracorporeal membrane oxygenation (ECMO) and anticoagulation was evaluated. Managing anticoagulation in neonates on ECMO is highly challenging due to their developing hemostatic system, placing them at significant risk for both life-threatening hemorrhage and thrombosis.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: